Celergenus

Celergenus is a biotechnology company focused on the development of next-generation gene therapies for rare genetic disorders, particularly neuromuscular diseases. The company utilizes proprietary adeno-associated virus (AAV) vector technology to deliver therapeutic genes, such as mini-dystrophin, to treat Duchenne Muscular Dystrophy (DMD). Founded by gene therapy pioneer Dr. Xiao Xiao, Celergenus aims to overcome the limitations of current treatments by optimizing vector potency and manufacturing scalability. Their research emphasizes high-efficiency gene delivery and long-term expression to improve patient outcomes in underserved populations.